Literature DB >> 21843522

Tumor-induced osteomalacia: The tumor may stay hidden!

Catherine van der Rest1, Etienne Cavalier, Jean-François Kaux, Jean-Marie Krzesinski, Roland Hustinx, Jean-Yves Reginster, Pierre Delanaye.   

Abstract

We report the case of a patient with severe muscular and articular tenderness that caused almost complete immobility. This subject had severe hypophosphatemia due to hyperphosphaturia. Fibroblast growth factor 23 (FGF-23) was abnormally high and the diagnostic of tumor-induced osteomalacia was made. Despite multiple tests, the tumor was not localized. In this report, we discuss different possible investigations to localize the tumor. Lastly, we review the potential therapy available when tumor is not found and can thus not be excised.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21843522     DOI: 10.1016/j.clinbiochem.2011.07.013

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  4 in total

Review 1.  FGF23 associated bone diseases.

Authors:  Eryuan Liao
Journal:  Front Med       Date:  2013-03-09       Impact factor: 4.592

Review 2.  Fibroblast growth factor 23 and bone mineralisation.

Authors:  Yu-Chen Guo; Quan Yuan
Journal:  Int J Oral Sci       Date:  2015-03-23       Impact factor: 6.344

3.  Rehabilitation of a Patient Receiving a Large-Resection Hip Prosthesis Because of a Phosphaturic Mesenchymal Tumor.

Authors:  Maurizio Lopresti; Primo Andrea Daolio; Jacopo M Rancati; Nicoletta Ligabue; Arnaldo Andreolli; Lorenzo Panella
Journal:  Clin Pract       Date:  2015-11-05

4.  Lessons learnt from delayed diagnosis of FGF-23-producing tumour-induced osteomalacia and post-operative hungry bone syndrome.

Authors:  S Kumar; T Diamond
Journal:  Bone Rep       Date:  2020-05-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.